The National Atomic Research Institute had held a Technical Investment Briefing Seminar on the "Dolacga Liver Imaging Agents" at 2:00 PM on Friday, October 20^th, at the Regent Taipei Hotel. You are cordially invited to attend.
 
“Dolacga Liver Imaging Agent”, a Taiwan-brand innovation by National Atomic Research Institute, is the first liver-targeted glycopeptide liver function test in the world. It can sensitively detect changes in the severity of liver diseases as an assessment of the severity of chronic hepatitis and liver cancer. It shows a more precise hepatoma scope, discriminates benignity from malignancy, and evaluates the function of a liver. It plays an important role on decision-making in future clinical diagnosis. Its all-in-one lyophilized design with the advantage of instant preparation of Ga-68 Dolacga has been patented across Taiwan, US, Europe and Japan. This agent won a gold medal of the Pharmaceutical Technology & Research Development award in 2022 jointly hosted by the Ministry of Economic Affairs and the Ministry of Health and Welfare in Taiwan.
 
To commercialize the achievements of the hepatic function imaging agent Dolacga, the National Atomic Research Institute entrusted the Development Center for Biotechnology to hold a drug technology briefing Seminar to promote drug licensing. We also arranged to visit companies interested in the development of radiopharmaceutical drugs to understand the needs and expectations of potential drug licensing partners, and to establish a deep cooperation relationship between the National Atomic Research Institute and the Taiwan nuclear medicine industry. Additionally, to address the legal and patent issues related to the shared patent of this drug with Johns Hopkins University, we have consulted a professional lawyer and patent agent familiar with drug licensing fields to develop negotiation strategies with Johns Hopkins University. We have also performed a comprehensive drug evaluation and checked the relevant patents for the hepatic function imaging agent Dolacga, carried out in-depth patent and competitor analysis, and understood the product positioning of Dolacga in the market to successfully commercialize the drug.
 
Details of the seminar are as follows:
Topic: Technology Investment Briefing Seminar of the "Dolacga Liver Imaging Agents"
Date: Friday, October 20^th , 2023
Time: 2:00 PM - 4:00 PM
Venue: VIP5 Hall, Regent Taipei Hotel (4F, No. 3, Lane 39, Section 2, Zhongshan North Road, Zhongshan District, Taipei City)
Organizer: National Nuclear Energy Research Institute
Co-organizer: Development Center for Biotechnology Foundation
Free admission.